Table 1.
Comparison between ILI, IFLPFP and IFLPFP2: distribution of patients according to risk, based on the original published data
| ILI(6) | IFLPFP(7) | IFLPFP2(9) | |
| Model definition | |||
| Age > 60 yrs | Age > 60 yrs | Age > 60 yrs | |
| ENS>2 | - | - | |
| Elevated LDH | Elevated LDH | - | |
| - | Stage III-IV | - | |
| - | Nodal sites > 4 | - | |
| Male gender | - | - | |
| - | Hb level < 12 g/dL | Hb level < 12 g/dL | |
| B symptoms | - | - | |
| ESR > 30 mm/h | - | - | |
| - | Elevated B2M | ||
| - | LoDLIN > 6 cm | ||
| BMI | |||
| Period of enrolment | |||
| 1985-1996 | 1985-1992 | 2003-2005 | |
| Initial study population (patients) | |||
| 987 | 5120 | 1093 | |
| Model population (patients) | |||
| 429 | 1795 | 832 | |
| Median follow-up (months) | |||
| 54 | 90 | 38 | |
| 5-year overall survival (%) | |||
| 77 | 71 | 88 | |
| Endpoint | |||
| OS | OS | PFS | |
| Patient distribution (%)§ | |||
| Low risk | 64 | 36 | 20 |
| Intermediate risk | 23 | 37 | 53 |
| High risk | 13 | 27 | 27 |
| 5-year survival* according to risk (%)§ | |||
| Low risk | 90 | 91 | 79 |
| Intermediate risk | 75 | 78 | 51 |
| High risk | 38 | 53 | 20 |
ILI - Italian Lymphoma Intergroup
IFLPFP - International Follicular Lymphoma Prognostic Factor Project
IFLPFP2 - International Follicular Lymphoma Prognostic Factor Project (phase-2 study)
ENS: Extra Nodal Sites; LDH: Lactic Dehydrogenase; Hb: Hemoglobin; B2M: β2-Microglobulin; LoDLIN: Longest diameter of the largest involved node; BMI: Bone Marrow Involvement: ESR: Erythrocyte Sedimentation Rate; OS: Overall Survival; PFS: Progression Free Survival
§= Low risk = 0-1 for ILI and IFLPFP and 0 for IFLPFP2; Intermediate risk = 2 for ILI and IFLPFP and 1-2 for IFLPFP2; High risk = 3-5 for all indexes. * OS for ILI and IFLPFP, PFS for IFLPFP2